Biotechnology

Aadi Biosciences

Aadi Biosciences to Release FY2024 Q4 Earnings on March 19 During-Market EST, Forecast Revenue 7.45 M USD, EPS -0.295 USD

All Proposals Approved at Aadi Bioscience Inc. Special Shareholder Meeting

Aadi proposes to sell FYARRO and related infrastructure to Kaken for $100 million

Aadi Biosciences released FY2024 9 Months Earnings on November 6 After-Market EST, with actual revenue of 18,744,000 USD and EPS of -1.6817

Aadi Biosciences released FY2024 Q3 earnings on November 6 After-Market (EST), actual revenue $7.212M (forecast $6.596M), actual EPS -0.4639 (forecast -0.4575)

Aadi Biosciences to Release FY2024 Q3 Earnings on November 6 After-Market EST, Forecast Revenue 6.596 M USD, EPS -0.4575 USD

Aadi Bioscience Downgraded to Neutral Rating

Aadi Bioscience Inc expects quarterly revenue to grow by 19.2% to $6.293 million

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AADI

MBIO

IBBQ

SBIO

ARKG

LABU

Advaita Bio has launched iSCanGuide, a cloud-based platform designed to streamline single-cell and spatial transcriptomics analysis. This GPU-accelerated platform integrates fragmented workflows, reducing analysis time from weeks to minutes. Key features include a user-friendly interface, standardized workflows, and support for various data formats. iSCanGuide connects to Advaita's iPathwayGuide for comprehensive pathway analysis, enhancing researchers' ability to derive insights from complex datasets. The platform aims to simplify the analysis process, making it accessible for both novice and expert users.

prnewswire

Mustang Bio

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Ark Genomic Revolution ETF

iShares Global Healthcare

SPDR S&P Biotech

VG Health

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

10X Genomics

07:45 ETAdvaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

Adia Nutrition, Inc. is seeking to acquire a larger property to expand its flagship clinic in Winter Park, Florida, aiming to enhance patient access to regenerative treatments and support growth. The company reported strong Q1 2026 performance with revenues of approximately $700,508, driven by biologic product sales and medical procedures. Key initiatives include new clinical studies and a partnership with an Atlanta clinic. The company anticipates continued growth in 2026, supported by the potential clinic expansion and strategic partnerships, while progressing towards a corporate name change to Adia Med, Inc.

StockTitan

Adia Nutrition, Inc. Looking to Acquire Larger Property to Expand Flagship Clinic in Winter Park, Reports Strong Operational Momentum in Q1 2026 and Provides Optimistic Outlook for Remainder of the Year | ADIA Stock News

Aadi Bioscience (NASDAQ:AADI) shares fell 2.5% to $3.90 during mid-day trading, with a trading volume of 316,496 shares, up 21% from the average. The stock's 50-day moving average is $3.37, and its market cap is $96.32 million. Aadi Bioscience focuses on developing precision medicines for genomically defined cancers, with its lead product candidate being fimepinostat. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investments.

Market Beat

Aadi Bioscience (NASDAQ:AADI) Stock Price Down 2.5%  - Here's What Happened

ADMA

BIOADAPTIVES reported revenue of $18,278 for 2025, with a net loss of $(1,557,898) and EPS of $(0.15). Despite a gross profit increase to $12,497, losses from operations widened due to higher expenses. The company is focusing on product development and marketing, with minimal revenue growth and strategic repositioning. New product rollouts are expected in Q2 2025, supported by ongoing clinical trials. The company also completed a reverse stock split and approved a stock dividend.

TradingView

Adma Biologics

BIOADAPTIVES 2025 10-K: Revenue $18,278, EPS $(0.15)

Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study | ADIA Stock News

Health Care Select Sector SPDR

Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study | ADIA Stock News

Adia Nutrition, Inc. reported significant revenue growth in its 2025 annual report, achieving approximately $700,508, up from $6,380 in 2024. This growth is attributed to increased sales in biologic products and medical procedures. The company has transitioned to a fully reporting entity under SEC regulations, enhancing transparency and potential for NASDAQ uplisting. Despite an operating loss of $366,492, management remains optimistic about future revenue momentum and ongoing investments in regenerative medicine. Adia Nutrition focuses on innovative healthcare solutions, including stem cell therapies and biologic products.

Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status | ADIA Stock News

Alligator Bioscience Updates Share Count After Warrant Exercise

Tip Ranks

APTOSE BIOSCIENCES INC

Alligator Bioscience Updates Share Count After Warrant Exercise

Alligator Bioscience AB will hold its annual general meeting on May 6, 2026, at 10:00 a.m. CEST in Lund, Sweden. Shareholders must be recorded in the share register by April 27, 2026, and notify the company of their intent to participate by April 29, 2026. The agenda includes the election of board members, approval of financial statements, and a proposal to carry forward an accumulated loss of SEK -83,280,054 without dividends. The Nomination Committee proposes four board members and unchanged remuneration for the board and committee work.

MorningStar

Abcellera Biologics

Direxion S&P Biotech Bear 3X

Notice of Annual General Meeting in Alligator Bioscience AB

Alligator Bioscience Adds Seasoned Pharma Leaders to Proposed Board Slate

Alligator Bioscience Adds Seasoned Pharma Leaders to Proposed Board Slate

Aadi Biosciences(AADI.US)

07:45 ETAdvaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

Adia Nutrition, Inc. Looking to Acquire Larger Property to Expand Flagship Clinic in Winter Park, Reports Strong Operational Momentum in Q1 2026 and Provides Optimistic Outlook for Remainder of the Year | ADIA Stock News

Aadi Bioscience (NASDAQ:AADI) Stock Price Down 2.5% - Here's What Happened

BIOADAPTIVES 2025 10-K: Revenue $18,278, EPS $(0.15)

Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study | ADIA Stock News

Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status | ADIA Stock News

Alligator Bioscience Updates Share Count After Warrant Exercise

Notice of Annual General Meeting in Alligator Bioscience AB

Alligator Bioscience Adds Seasoned Pharma Leaders to Proposed Board Slate